These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18838589)

  • 1. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
    Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of a significant drug interaction between raltegravir and tenofovir.
    Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
    de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
    Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
    Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M
    J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
    Wenning LA; Petry AS; Kost JT; Jin B; Breidinger SA; DeLepeleire I; Carlini EJ; Young S; Rushmore T; Wagner F; Lunde NM; Bieberdorf F; Greenberg H; Stone JA; Wagner JA; Iwamoto M
    Clin Pharmacol Ther; 2009 Jun; 85(6):623-7. PubMed ID: 19279563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
    Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors.
    Calcagno A; Tettoni MC; Simiele M; Trentini L; Montrucchio C; D'Avolio A; Di Perri G; Bonora S
    J Antimicrob Chemother; 2013 Feb; 68(2):482-4. PubMed ID: 23085776
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
    Iwamoto M; Hanley WD; Petry AS; Friedman EJ; Kost JT; Breidinger SA; Lasseter KC; Robson R; Lunde NM; Wenning LA; Stone JA; Wagner JA
    Antimicrob Agents Chemother; 2009 May; 53(5):1747-52. PubMed ID: 19223645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir as effective as efavirenz in 144-week data.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
    Jackson A; Watson V; Back D; Khoo S; Liptrott N; Egan D; Gedela K; Higgs C; Abbas R; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2011 Dec; 58(5):450-7. PubMed ID: 21926632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.
    Lee LS; Soon GH; Shen P; Yong EL; Flexner C; Pham P
    Antivir Ther; 2010; 15(2):275-9. PubMed ID: 20386083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.
    la Porte CJ; de Graaff-Teulen MJ; Colbers EP; Voncken DS; Ibanez SM; Koopmans PP; Hekster YA; Burger DM
    Br J Clin Pharmacol; 2004 Dec; 58(6):632-40. PubMed ID: 15563361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.
    Krishna R; East L; Larson P; Siringhaus T; Herpok L; Bethel-Brown C; Manthos H; Brejda J; Gartner M
    Biopharm Drug Dispos; 2016 Dec; 37(9):542-549. PubMed ID: 27704562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.